Evercore ISI Issues Positive Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV - Free Report) had its price objective upped by Evercore ISI from $170.00 to $180.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the medical research company's stock.

Several other analysts also recently issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Wall Street Zen lowered IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Barclays lowered their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Finally, Mizuho lowered their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $222.45.

IQVIA Stock Up 2.2%

IQV traded up $3.51 during midday trading on Wednesday, hitting $165.53. 1,612,122 shares of the company's stock traded hands, compared to its average volume of 1,659,031. IQVIA has a one year low of $134.65 and a one year high of $252.88. The stock's fifty day simple moving average is $151.77 and its 200-day simple moving average is $172.43. The company has a market cap of $28.64 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.80 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 earnings per share. As a group, equities analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the 1st quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.